CREATE Medicines secured a $122 million Series B round to expand its in vivo immune programming platform across autoimmune disease and oncology. The company’s mRNA-LNP approach is designed to engineer CAR T and related immune populations inside the body, with repeat dosing intended to enable immune reset. CREATE’s lead autoimmune program, CRT-402, is CD19-targeted in vivo CAR T, with non-human primate data showing deep and durable B cell depletion. A second autoimmune program targets CD19 and BCMA for refractory autoimmune diseases, while oncology programs include MT-303 in frontline hepatocellular carcinoma. The company said it has dosed more than 50 patients across its in vivo CAR clinical programs, and the financing is intended to maintain momentum toward near-term clinical expansion. Funding supports continued investment in internal manufacturing alongside pipeline progression.